Janney Montgomery Scott Downgrades Innocoll (INNL) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
FBR Capital Downgrades Innocoll (INNL) to Market Perform
December 30, 2016 8:19 AM ESTFBR Capital downgraded Innocoll (NASDAQ: INNL) from Outperform to Market Perform with a price target of $2.00 (from $10.00) after the company received a Refusal to File letter from the United States Food and Drug Administration (FDA) for XARACOLL, the companys product candidate for the... More
JMP Securities Downgrades Innocoll (INNL) to Market Perform; XARACOLL Approval Delayed at Least 6-12 Months
December 30, 2016 7:15 AM ESTJMP Securities downgraded Innocoll (NASDAQ: INNL) from Market Outperform to Market Perform.
Analyst Jason Butler said the FDA refuse-to-file letter likely delays XARACOLL approval by at least 6-12 months.
"While we currently view the potential requirement for an... More
Innocoll AG (INNL) Receives Refusal to File Letter from FDA on XARACOLL NDA
December 29, 2016 5:03 PM ESTInnocoll (NASDAQ: INNL) received a Refusal to File letter from the United States Food and Drug Administration (FDA) for XARACOLL, the companys product candidate for the treatment of postsurgical pain.
Upon preliminary review, the FDA determined that the application,... More
